longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Veru

VERU

2.5391.59% ( -0.041 )
Trading: Sep 9, 15:16:53 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -3.23, below the reasonable range, cheaper than 84.67% of the time in the past 1 years, and the industry ranks 141/258, the industry Median -1.52.

-3.23xP/E
$2.58Stock price
$-0.80Earnings per share
-3.23xP/E
Stock price$2.58Earnings per share$-0.80

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.92x
Typical range
-2.74x–-1.60x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-55.43x14.01%$57.88B
BAYRYUSBayer
-27.89x--$56.27B
BAYZFUSBayer Aktiengesellschaft
-27.51x--$55.50B
VTRSUSViatris
-46.45x107.02%$19.08B
ELANUSElanco Animal Health
-60.18x129.36%$11.98B
VREOFUSVIREO GROWTH INC
-173.66x--$11.65B
AXSMUSAxsome Therap
-56.80x27.32%$10.89B
BLTEUSBelite Bio
-75.87x29.87%$7.77B
CURLFUSCuraleaf Holdings, Inc.
-146.54x--$7.62B
DFTXUSDefinium Therapeutics
-14.52x53.67%$5.14B
EWTXUSEdgewise Therapeutics
-24.13x137.29%$4.76B
ELVNUSEnliven Therapeutics
-41.07x1.17%$4.35B
MANEUSVeraDermics
-41.60x97.39%$4.34B
AMLXUSAmylyx Pharmaceuticals
-27.96x1.76%$4.25B
TARSUSTarsus Pharmaceuticals
-82.35x34.09%$3.83B
RGCUSRegencell Bioscience
-479.41x--$3.38B
MBXUSMBX Biosciences
-29.09x32.19%$3.03B
GPCRUSStructure Therapeutics
-13.40x104.48%$2.88B
ATAIUSAtaiBeckley
-4.04x86.14%$2.70B
PHVSUSPharvaris BV
-13.39x7.47%$2.66B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.